Carcinoma of the penis primary prevention

Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [mailto:mgibson@perfuse.org] Phone:617-632-7753; Joel Gelman, M.D. [mailto:jgelman@uci.edu], Director of the Center for Reconstructive Urology and Associate Clinical Professor in the Department of Urology at the University of   California,Irvine

Vaccine
A quadri-valent vaccine to prevent HPV infection, Gardasil, has been developed, successfully tested and approved for women by the US Food and Drug Administration. Approval for men is expected in 2008. It is licensed and in production, and could substantially reduce the incidence of HPV infection in men, the incidence of genital warts and ano-genital cancers including penile cancer, and mortality. It is unclear why the drug's manufacturer chose to stagger testing of the vaccine, potentially leaving many men needlessly vulnerable to HPV infection.